3D printing and pharmaceuticals

|

article image
The new technology will transform manufacturing and the supply chain, creating significant tax implications for companies. What if tangible goods moved digitally across borders? If centralized production migrated to local markets? If products could be customized in real time? What if distributors or even individual consumers produced a corporation’s goods? For many companies, this is what the future will look like thanks to 3D printing, also known as print on demand. 3D printing is set to transform manufacturing and supply chains as we know them, creating significant tax implications for companies.

Spotlight

Terumo Medical Corporation

Terumo Medical Corporation (TMC) was established in 1972 as a U.S. subsidiary of Tokyo-based Terumo Corporation, one of the world’s leading medical device manufacturers. TMC develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets.

OTHER ARTICLES

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | April 17, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | April 17, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | April 17, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

Terumo Medical Corporation

Terumo Medical Corporation (TMC) was established in 1972 as a U.S. subsidiary of Tokyo-based Terumo Corporation, one of the world’s leading medical device manufacturers. TMC develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets.

Events